First Settlements of Levaquin Trials Find Fault With Warnings

An antibiotic sold since 1997 is the subject of a proposed class action that argues the drug causes a higher incidence of tendon injuries. Levaquin, a broad spectrum fluoroquinolone antibiotic, is marketed as a first-line therapy for common bronchitis and sinusitis infections. It is also approved for the use in treatment of various upper respiratory infections, urinary tract infections, prostatitis and other bacterial infections. Many injured parties continue to seek legal council in order to file a Levaquin lawsuit throughout the United States against Johnson & Johnson and Ortho-McNeil Pharmaceuticals over problems with Levaquin tendon ruptures. According to court documents, there are currently over 1500 Levaquin injury lawsuits pending in federal court, with hundreds more expected to be filed in the coming months.

New Jersey to See Levaquin Trials Go Forward

Sometime this month or early next month, the first of the New Jersey Levaquin lawsuit trials will begin with a combination of claims brought by Bob Beare and Paul Gaffney. Many plaintiffs, like Beare and Gaffney allege that they were inadequately warned about known risks associated with taking Levaquin. Levaquin tendon side effects, including increased risk of tendon damage and tendon ruptures, particularly involving the Achilles tendon. Levaquin is part of a class of antibiotics known as fluoroquinolones.  Although many of the reported cases of tendon ruptures have been associated with the use of Levaquin, the side effects have also been seen with the use of other antibiotics which are part of this class.